MYD88 and goblet cell carcinoma: Different from the study results in hepatocellular carcinoma and epithelial ovarian cancer in which recurrence rate was higher and recurrence-free survival and overall survival were poorer in patients with MyD88 overexpression (8), we showed that the expression of MyD88 did not correlate with survival of GCC patients.